"Genentech provides a highly collaborative, fast-paced and scientifically rigorous environment that allows people to grow both personally and professionally. The scientists here are driven to succeed, innovative and, most importantly, curious."
I joined Genentech in 2010 after being on staff at the University of Minnesota, College of Veterinary Medicine, working in the field of comparative cancer biology and pathology. I have always been interested in animal models of human disease, particularly cancer, and was increasingly motivated to transition from basic research to translational research where I could focus my efforts on developing cancer drugs for human patients. I was drawn to Genentech by its reputation for being scientifically rigorous and collaborative, as well as being highly successful at bringing novel oncology therapies to market. I have been working in cancer drug research and development, mainly on the antibody drug conjugate platform, since 2010.
2016. Tox. Path. Feb; 44(2) 267-78.
My areas of interest and expertise are in comparative pathology, veterinary medicine, and cancer biology. I work in close collaboration with colleagues throughout safety assessment toxicology, nonclinical operations and research to drive the development of effective, safe, and novel oncology therapeutics. I am also actively involved with internal and cross-industry efforts focused on improving overall drug development efficiency. In addition, I regularly mentor veterinary students, residents and/or graduate students through externships and oversight of toxicologic pathology-related investigative studies.